Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van Sells 1,245 Shares

Posted by on Aug 2nd, 2023

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) CFO Houte Hans Van sold 1,245 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $9.65, for a total transaction of $12,014.25. Following the sale, the chief financial officer now directly owns 82,571 shares of the company’s stock, valued at approximately $796,810.15. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX opened at $9.50 on Wednesday. Nurix Therapeutics, Inc. has a 52 week low of $8.34 and a 52 week high of $19.91. The stock’s 50-day moving average price is $10.13 and its 200-day moving average price is $10.18.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last announced its earnings results on Thursday, July 13th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.12. The company had revenue of $30.68 million for the quarter, compared to analyst estimates of $21.96 million. Nurix Therapeutics had a negative return on equity of 53.36% and a negative net margin of 258.37%. As a group, equities research analysts anticipate that Nurix Therapeutics, Inc. will post -2.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Nurix Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Swiss National Bank raised its holdings in Nurix Therapeutics by 7.8% during the fourth quarter. Swiss National Bank now owns 85,200 shares of the company’s stock worth $935,000 after purchasing an additional 6,200 shares in the last quarter. Russell Investments Group Ltd. grew its position in Nurix Therapeutics by 2,640.5% during the fourth quarter. Russell Investments Group Ltd. now owns 24,089 shares of the company’s stock worth $264,000 after buying an additional 23,210 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Nurix Therapeutics by 23.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,312 shares of the company’s stock worth $69,000 after buying an additional 1,194 shares during the period. Denali Advisors LLC grew its position in Nurix Therapeutics by 63.9% during the fourth quarter. Denali Advisors LLC now owns 5,900 shares of the company’s stock worth $65,000 after buying an additional 2,300 shares during the period. Finally, Los Angeles Capital Management LLC grew its position in Nurix Therapeutics by 57.4% during the fourth quarter. Los Angeles Capital Management LLC now owns 106,479 shares of the company’s stock worth $1,169,000 after buying an additional 38,824 shares during the period. 89.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NRIX has been the subject of several analyst reports. HC Wainwright reduced their target price on shares of Nurix Therapeutics from $53.00 to $33.00 and set a “buy” rating for the company in a report on Monday, July 24th. Royal Bank of Canada restated an “outperform” rating and issued a $30.00 price target on shares of Nurix Therapeutics in a research note on Friday, April 14th. Finally, Needham & Company LLC restated a “buy” rating and issued a $31.00 price target on shares of Nurix Therapeutics in a research note on Friday, April 21st. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $27.22.

Nurix Therapeutics Company Profile

(Get Free Report)

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

Read More

Insider Buying and Selling by Quarter for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.